Mini Review Article

Public Health issues in hospital management of Sarcopenic patients

Vassiliki Marinaki1, George I. Lambrou2

1Fifth Orthopedic Department & Spinal Cord Injury Department, “KAT” Hospital, Nikis 2, Kifisia; 2First Department of Pediatrics, Choremeio Research Laboratory, National and Kapodistrian University of Athens, Greece

Abstract

Sarcopenia is a combination of a progressive and generalized loss of skeletal muscle mass and muscle strength or physical performance, with high risk of adverse outcomes such as physical disability, poor quality of life and death. It mainly affects older people, aged 60-70 years. The development of sarcopenia is multifactor. The first step towards the management of sarcopenia is the proper and professional diagnosis. According to EWGSOP the diagnosis of sarcopenia depends on the presence of low muscle mass (LMM) plus low muscle strength (LMS) or low physical performance (LPP). Although it is difficult to establish its prevalence, the higher prevalence is observed in hospitalized elderly patients. It has direct and indirect impact on public health, which are difficult to be measured due to numerous negative outcomes of sarcopenia.

Keywords: Sarcopenia, Public Health, Management, Public Health Expenditure, Quality of Life

Introduction

The term sarcopenia is derived from the Greek word Σάρξ meaning “flesh” and Πενία (penia) meaning “poverty”. It was described for the first time by Rosenberg in 19891,2, referring to age related loss of skeletal muscle mass3. However, over the last decades, there was no widely accepted definition of sarcopenia4.

The European Working Group on Sarcopenia in Older People (EWGSOP) provided a definition of sarcopenia in 2010; “A combination of a progressive and generalized loss of skeletal muscle mass and muscle strength or physical performance, with high risk of adverse outcomes such as physical disability, poor quality of life and death”5. Sarcopenia is known to be a new geriatric syndrome6, as it mainly affects older people, aged 60-70 years, on an average of 5-13%7. It is reported that 5-13% of people over 60 years of ages have low muscle mass, while the average rises to 50% in patients over 80 years8. The decrease of muscle mass is accompanied with loss in muscle strength, aerobic capacity and metabolic rate that lead to reduced muscle function9. The percentages are higher as far as the decline in muscle strength during the ages is concerned7. Although sarcopenia affects mostly older people, it can also be present in young adults, from the fourth decade of life, according to a recent study by Cherin et al. (2014)10.

Sarcopenia can be divided into two main categories; primary and secondary. Primary sarcopenia includes cases where aging is the only apparent reason for its clinical manifestation, whereas secondary sarcopenia includes cases where further pathologies coexist11. Secondary sarcopenia includes activity-related, disease-related, and nutrition-related sarcopenia12. The EWGSOP suggested the separation of sarcopenia in three stages: a) Pre-sarcopenia, which includes only low muscle mass, without any muscle strength or performance dysfunctions, b) Sarcopenia, which is defined as the presence of low muscle mass and low muscle strength or physical performance and c) Severe sarcopenia, which includes all three criteria11.

The authors have no conflict of interest.

Corresponding author: George I. Lambrou, First Department of Pediatrics, Choremeio Research Laboratory, National and Kapodistrian University of Athens, Thivon & Levadeias, 11527, Goudi, Athens, Greece

E-mail: glamrou@med.uoa.gr

Edited by: Yannis Dionyssiotis

Accepted 16 August 2017
Etiology of Sarcopenia

The development of sarcopenia is considered to be the result of several factors including the genetic background\(^{13}\), age-related hormones\(^{14,16}\), nutrition\(^{14-16}\), neurodegeneration\(^{5,17}\), chronic diseases\(^{15,18}\) and disability, immobility and lack of physical activity\(^{19}\).

Diagnostic Criteria

The first step towards the management of sarcopenia is the proper and professional diagnosis. According to EWGSOP the diagnosis of sarcopenia depends on the presence of low muscle mass (LMM) plus low muscle strength (LMS) or low physical performance (LPP)\(^{20}\).

Muscle mass

There are three available imaging techniques to estimate muscle mass. Dual energy x-ray absorptiometry (DXA) measures precisely the body composition\(^{21}\). Although, DXA may overestimate skeletal muscle due to the difficulty in distinguishing muscle from water retention. It is a cheap method but there is lack of equipment\(^{14}\).

The gold standard for measuring muscle mass is the Magnetic Resonance Imaging (MRI), without radiation exposure. Drawbacks of MRI are the high cost and the need of specialized staff and specific software, as well it is time consuming\(^{22}\). Computed Tomography (CT) is also very precise in measuring muscle mass, but not only it is an expensive method but also is associated with high radiation exposure\(^{21}\).

Bioimpedance analysis estimates the volume of fat and lean body mass by dividing the skeletal muscle by the square of height\(^{23}\). Bioimpedance is easy to use, it can be used at the bedside without expose to radiation. But it is not very accurate, as it can be biased by the hydration status and the presence of edema\(^{24}\). Total body potassium (TBK) is another method for measuring skeletal muscle, as skeletal muscle contains approximately 50% of the total body potassium pool. Although, it is easy to use, it is not common\(^{11}\).

Muscle strength

Handgrip strength is a simple and very practical method of measuring muscle strength. The Jamar dynamometer is the most well-known device\(^{24,25}\). Knee flexion/extension is another way of estimating muscle strength either isometrically or isokinetically. However, it requires special equipment and staff.

Prevalence of Sarcopenia

Although, sarcopenia is mostly observed in older ages, it is still difficult to establish its prevalence\(^{26}\). This difficulty, as a consequence of the different diagnostic criteria, rises from the heterogeneity of the studied population\(^{27}\). Prevalence of sarcopenia in older people is estimated to range between 1 and 29%. This percentage increases for older people, aged over 80 years\(^{28}\). Higher prevalence of sarcopenia is observed in hospitalized elderly patients\(^{27}\).

In general, prevalence of sarcopenia depends on various parameters, such as: a) Sex, where men have higher prevalence as compared to women, b) Age, where older individuals tend to be more prevalent for sarcopenia, while this tendency decreases with decreasing age. Yet, in a recent report by Cherin P et al. (2014) is has been found that one out of five patients aged under 65 years was sarcopenic\(^{20}\).

Diagnostic Criteria

The first step towards the management of sarcopenia is the proper and professional diagnosis. According to EWGSOP the diagnosis of sarcopenia depends on the presence of low muscle mass (LMM) plus low muscle strength (LMS) or low physical performance (LPP)\(^{20}\).

Diagnostic Criteria

The first step towards the management of sarcopenia is the proper and professional diagnosis. According to EWGSOP the diagnosis of sarcopenia depends on the presence of low muscle mass (LMM) plus low muscle strength (LMS) or low physical performance (LPP)\(^{20}\).

Impact on public health

Direct impact

There is a lack of data concerning the impact of sarcopenia in the public health system. The only published study concerns the United States of America (USA), which may be representative for other developed countries. This research showed that in the USA the public health expenditure of sarcopenia is estimated to be $18.5 billion, which is estimated to be divided to $8 billion for males and $7.75 billion for females in the year 2000. This expenditure corresponds to the 1.5% of total health care cost in the United States in 2000. It has been also reported that “… reducing the prevalence of sarcopenia by 10% would result in savings of $1.1 billion per year in USA healthcare cost”. Comparatively, it is worth mentioning that in the same year the total healthcare expenditure for osteoporotic fractures in the USA was $16.3 billion\(^{11}\).

Indirect impact

Sarcopenia has also numerous negative outcomes that have a major impact on public health including consequences in personal level, in the social and health care system. Sarcopenia is related to many comorbidities, such as physical disability, high risk of falls, depression, hospitalization\(^{32}\) bad quality of life, loss of productivity\(^{29}\) and mortality. In particular, sarcopenia is linked with physical disability\(^{24}\) that is associated with increased health care cost, more as outpatient. It has been estimated that over 75% of those will use home health services\(^{35}\). Sarcopenia is also associated with loss of impendence and inability of doing...
daily life activities. Sarcopenia is related with great risk of falls with the subsequent outcomes of it, which increase the health care cost. Another indirect impact of sarcopenia on public health is the comorbidities that are associated with it. Sarcopenia usually coexist with osteoporosis and high risk of hip fracture. According to a recent study of Oliveira et al. (2015), there is a significant association between sarcopenia and hip fractures. The higher risk of fracture has as a consequence the increased risk of hospitalization, leading to a rise of health care expenditure. Sarcopenia is also associated with other diseases and predicts poor outcomes is some of them. Endocrine diseases, especially diabetes, kidney diseases, coronary heart diseases are linked with sarcopenia and affect negatively the outcomes. Sarcopenia, also, may interactively correlate with the presence and severity of age-related osteoarthritis. It is also associated with high risk of poor outcomes in severe liver disease. Sarcopenia is strongly linked with frailty, an age related syndrome which is characterized by lack of adaptive capacity of the organism. Frailty is also associated with high risk of hospitalization and increased health care costs.

In a recent study Sanchez-Rodriguez et al. using the ESPEN criteria for the definition of malnutrition and EWGSOP criteria for the definition of sarcopenia, drawn the conclusion that “...sarcopenia and malnutrition are related conditions, as most patients with sarcopenia fulfilled the ESPEN criteria for a diagnosis of malnutrition”. Malnutrition is also one of the major factors of development age related diseases, such as sarcopenia. More specific, the cycle of frailty starts with chronic malnutrition, that in turn leads to sarcopenia. The health care cost of malnutrition must be taken into consideration in the cost and consequences of sarcopenia. Malnutrition affects every system of the human body, is both a cause and consequence of diseases and increases the risk of delaying recovery and poor outcomes, almost 70% are more likely for long-term stay in hospital, placing increased demands on hospital. All these lead to increased health care cost (Institute of Food and Health Policy 2009).

As it was mentioned before, frailty malnutrition and falls are associated with high risk of hospitalization. Moreover, sarcopenia its own presents also high risk of hospitalization. Poor physical condition leads to longer hospital stay for almost 20 days, that it means raise in health care cost. Mortality is predicted to be higher in middle aged individuals and older adults suffering from sarcopenia. A recent study confirmed that hospitalized patients with sarcopenia present a higher mortality rate as compared to hospitalized individuals without sarcopenia after one year postdischarge. In addition, there is a strong association between the severity of sarcopenia and mortality.

As life expectancy increases, it is necessary for the public sector to invest to research for the prevention and treatment of sarcopenia. Public health expenditure and consequences of sarcopenia are considered to be direct and indirect. Up to date, expenditure estimation concerns the direct cost of sarcopenia, since the indirect cost is much complicated to be evaluated. Considering all these, is difficult to measure the real impact of sarcopenia on health care system.

Authors’ contributions: MV: collected literature, drafted the document, performed literature research. GIL: drafted the document, gave final permission for submission.

References
1. Rosenberg IH. Summary comments. The American journal of clinical nutrition 1989;50(5):1231-3.
2. Sousa AS, et al. Sarcopenia among hospitalized patients - A cross-sectional study. Clinical nutrition (Edinburgh, Scotland) 2015;34(6):1239-44.
3. Berger MJ, et al. Sarcopenia: prevalence, mechanisms, and functional consequences. Interdisciplinary topics in gerontology 2010;37:94-114.
4. Cruz-Jentoft AJ, et al. Prevalence of and interventions for sarcopenia in ageing adults: a systematic review. Report of the International Sarcopenia Initiative (EWGSOP and IWGS). Age and ageing 2014;43(6):748-59.
5. Lang T, et al. Sarcopenia: etiology, clinical consequences, intervention, and assessment. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2010;21(4):543-59.
6. Chen LK, et al. Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia. Journal of the American Medical Directors Association 2014;15(2):95-101.
7. von Haehling S, et al. An overview of sarcopenia: facts and numbers on prevalence and clinical impact. Journal of cachexia, sarcopenia and muscle 2010;1(2):129-33.
8. Morley JE, et al. Prevalence, incidence, and clinical impact of sarcopenia: facts, numbers, and epidemiology-update 2014. Journal of cachexia, sarcopenia and muscle 2014;5(4):253-9.
9. Gumucio JP, et al. Atrogin-1, MuRF-1, and sarcopenia. Endocrine related to nutrition and activities of daily living of elderly individuals. Journal of physical therapy science 2015;27(2):393-6.
10. Cherin P, et al. Prevalence of sarcopenia among healthy ambulatory subjects: the sarcopenia begins from 45 years. Aging clinical and experimental research 2010;21(4):137-46.
11. Cruz-Jentoft AJ, et al. Sarcopenia: European consensus on definition and diagnosis. Report of the European Working Group on Sarcopenia in Older People. Age and ageing 2010;39(4):412-23.
12. Shiozzi H, et al. Association of sarcopenia with swallowing problems, related to nutrition and activities of daily living of elderly individuals. Journal of physical therapy science 2015;27(2):393-6.
13. Huygens W, et al. Quantitative trait loci for human muscle strength: linkage analysis of myostatin pathway genes. Physiological genomics 2005;22(3):390-7.
14. Landi F, et al. Sarcopenia as a risk factor for falls in elderly individuals: results from the iSiRENTE study. Clinical nutrition (Edinburgh, Scotland) 2012;31(5):652-8.
15. Scott D, et al. The epidemiology of sarcopenia in community living older adults: what role does lifestyle play? Journal of cachexia, sarcopenia and muscle 2011;2(3):125-34.
16. Ho AW, et al. Prevalence of pre-sarcopenia and sarcopenia in Hong Kong Chinese geriatric patients with hip fracture and its correlation with different factors. Hong Kong medical journal = Xianggang yi xue
17. Argiles JM, et al. Cachexia and sarcopenia: mechanisms and potential targets for intervention. Current opinion in pharmacology 2015;22:100-6.
18. Rizzoli R, et al. Quality of life in sarcopenia and frailty. Calcified tissue international 2013;93(2):101-20.
19. Phillips SM. Nutrient-rich meat proteins in offsetting age-related muscle loss. Meat science 2012;92(3):174-8.
20. da Silva Alexandre T, et al. Sarcopenia according to the european working group on sarcopenia in older people (EWGSOP) versus Dynapenia as a risk factor for disability in the elderly. The journal of nutrition, health & aging 2014;18(5):547-53.
21. Vellas B, et al. Designing pharmaceutical trials for sarcopenia in frail older adults: EU/US Task Force recommendations. The journal of nutrition, health & aging 2013;17(7):612-8.
22. Wall BT, et al. Skeletal muscle atrophy during short-term disuse: implications for age-related sarcopenia. Ageing research reviews 2013;12(4):898-906.
23. Roberts H, et al. Assessment and management of older people with sarcopenia. Nursing older people 2014;26(5):18, 20-2.
24. Dodds R, et al. Sarcopenia and frailty: new challenges for clinical practice. Clinical medicine (London, England) 2015;15 Suppl 6:s88-91.
25. Dodds R, et al. Sarcopenia and frailty: new challenges for clinical practice. Clinical medicine (London, England) 2016;16(5):271-8.
26. Beaudart C, et al. Sarcopenia burden and challenges for public health. Archives of public health = Archives belges de sante publique 2014;72(1):45.
27. Beaudart C, et al. Prevalence of sarcopenia: the impact of different diagnostic cut-off limits. Journal of musculoskeletal & neuronal interactions 2014;14(4):425-31.
28. Dorosty A, et al. Prevalence of Sarcopenia and Its Association with Socioeconomic Status among the Elderly in Tehran. Ethiopian journal of health sciences 2016;26(4):389-96.
29. Rejirister JY, et al. Osteoporosis and sarcopenia: two diseases or one? Current opinion in clinical nutrition and metabolic care 2016;19(1):31-6.
30. Tegels JJ, et al. Sarcopenia is highly prevalent in patients undergoing surgery for gastric cancer but not associated with worse outcomes. Journal of surgical oncology 2015;112(4):403-7.
31. Janssen I, et al. The healthcare costs of sarcopenia in the United States. Journal of the American Geriatrics Society 2004;52(1):80-5.
32. Ethgen O, et al. The Future Prevalence of Sarcopenia in Europe: A Claim for Public Health Action. Calcified tissue international 2017;100(3):229-34.
33. Beaudart C, et al. Quality of life and physical components linked to sarcopenia: The SarcoPhAge study. Experimental gerontology 2015;69:103-10.
34. Tanimoto Y, et al. Sarcopenia and falls in community-dwelling elderly subjects in Japan: Defining sarcopenia according to criteria of the European Working Group on Sarcopenia in Older People. Archives of gerontology and geriatrics 2014;59(2):295-9.
35. Chan L, et al. Disability and health care costs in the Medicare population. Archives of physical medicine and rehabilitation 2002;83(9):1196-201.
36. Bruyère O, et al. Sarcopenia as a public health problem. European Geriatric Medicine 2016;7(3):272-5.
37. Oliveira A, et al. The role of sarcopenia in the risk of osteoporotic hip fracture. Clinical rheumatology 2015;34(10):1673-80.
38. Kim HT, et al. An analysis of age-related loss of skeletal muscle mass and its significance on osteoarthritis in a Korean population. The Korean journal of internal medicine 2016;31(3):585-93.
39. Englesbe MJ, et al. Sarcopenia and mortality after liver transplantation. Journal of the American College of Surgeons 2010;211(2):271-8.
40. Berrabah R, et al. Frailty, Physical Frailty, Sarcopenia: A New Conceptual Model. Studies in health technology and informatics 2014;203:78-84.
41. Bock JO, et al. Associations of frailty with health care costs - results of the ESTHER cohort study. BMC health services research 2016;16:128.
42. Sanchez-Rodriguez D, et al. Prevalence of malnutrition and sarcopenia in a post-acute care geniatric unit: Applying the new ESPEN definition and EWGSOP criteria. Clinical nutrition (Edinburgh, Scotland) 2015;34(4):539-50.
43. Beaudart C, et al. Health Outcomes of Sarcopenia: A Systematic Review and Meta-Analysis. PloS one 2017;12(1):e0169548.
44. Vetrano DL, et al. Association of sarcopenia with short- and long-term mortality in older adults admitted to acute care wards: results from the CRIME study. The journals of gerontology Series A, Biological sciences and medical sciences 2014;69(9):1154-61.